Friday, April 28, 2017 9:57:39 AM
It's important to remember the application of R18! We're talking
about individuals, who face a very high probability of death (after
exposure to radiation), and subjective reactions, such as blurred
vision will not be decisive.
I'm sure they did do a massive number of tests to see if any
significant biological indicators were negatively effected,
and they say, no, things are looking good.
My feeling is that due to the issues with N.Korea, the threat
of terrorists with dirty bombs, and the possibility of industrial
accidents, it would be the height of irresponsibility NOT to
have a good supply of R18 stashed away and ready to be
used. Waiting till 2019 to start building up a supply of R-18
and at the same time giving Pluristam the means to scale
up their production capabilities cannot wait (at least if I
was in charge!).
Safety studies can continue even as the responsible agencies
acquire a supply of the stuff, just in case...!
That would be my argument for pps relevant news much earlier
than 2019.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM